Oncology

CAR-T therapy
#Cancer research #Guide #Oncology

Guide: Discover the latest advances in cancer research

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics. New modalities, like radiopharmaceuticals, alongside new drug targets, like… Read More

#News

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#Coiled Therapeutics #Drug discovery #Oncology #Precision medicine

Coiled Therapeutics completes transition to clinical-stage company

Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange.  Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary Share with institutional… Read More

#Business & Investment #News #Start-up Zone

Ovarian cancer
#Corcept Therapeutics #FDA #Oncology #Ovarian cancer

Platinum-resistant ovarian cancer drug gets FDA green light

The US Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment regimens, at least one of which… Read More

#News #Regulatory

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions #Oncology

AstraZeneca buys in vivo cell therapy specialists EsoBiotec

AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T… Read More

#Business & Investment #News

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

CAR-T in multiple myeloma
#Biotech #Cancer research #CAR-T #Drug discovery #Oncology

The next generation of CAR-T cell therapies

Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space.   RA: What are the biggest challenges when developing CAR-T cell therapies?   JDM: CAR-T therapies face several formidable barriers. Autologous approaches made from a patient’s own T-cells are… Read More

#Exclusive Content

Prostate cancer conceptualisation
#Oncology #Prostate cancer #Texas A&M University Health Science Center

Research uncovers how prostate cancer cells resist treatment

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some tumours progress and become resistant to treatment.  The study, led by Ziying Liu, a former student in the lab of Fen… Read More

#Cancer Research #Editor's Choice #News

Novartis head office
#Mergers and acquisitions #Novartis #Oncology #Solid tumours #Synnovation Therapeutics

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion

Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818.  Pikavation is a wholly-owned subsidiary of Synnovation.  SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase I/II clinical trials for the treatment of HR+/HER2- metastatic breast… Read More

#Business & Investment #News

#Biotech #Drug discovery #Financing #Oncology

Laigo Bio raises $17m to advance oncology pipeline  

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will also advance three… Read More

#Business & Investment #News

#AI #Oncology #Precision medicine

Collaboration to advance precision oncology therapy 

Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.  The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.  TH9619, developed by One-carbon Therapeutics, is a first-in-class,… Read More

#Business & Investment #News

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

DDW Cancer Research Guide
#Cancer research #Guide #Oncology

Guide: Advances in cancer research

This DDW guide explores the latest advancements in cancer research, including an overview of recent market developments, how to selectively degrade essential proteins, the potential of KRAS inhibitors and novel approaches to radiotherapy.

#DDW eBooks #DDW Guides

Multiple myeloma
#Cancer drug targets #HaemaLogiX #Haematology #Myeloma #Oncology

Research identifies new targets for multiple myeloma treatment

New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.  These antigens are present on malignant plasma cells but… Read More

#Cancer Research #News